Rakovina Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Mar '26 Mar 6, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Market Capitalization	3	27	6	13	15	-	Upgrade
Market Cap Growth	-89.04%	348.09%	-52.61%	-18.16%	-	-	Upgrade
Enterprise Value	5	28	6	11	12	-	Upgrade
Last Close Price	0.14	1.90	0.85	1.80	2.20	-	Upgrade
PB Ratio	1.51	6.21	1.63	2.09	1.80	-	Upgrade
P/TBV Ratio	-	83.04	-	13.06	5.19	-	Upgrade
Debt / Equity Ratio	1.38	0.33	0.36	-	-	-	Upgrade
Net Debt / Equity Ratio	0.94	0.03	0.25	-0.15	-0.33	0.58	Upgrade
Net Debt / EBITDA Ratio	-0.24	-0.03	-0.46	0.39	1.36	-	Upgrade
Quick Ratio	0.45	0.72	2.95	8.52	25.32	0.40	Upgrade
Current Ratio	0.78	1.17	4.09	9.99	26.94	0.40	Upgrade
Return on Equity (ROE)	-333.54%	-102.34%	-54.02%	-38.35%	-129.24%	-	Upgrade
Return on Assets (ROA)	-93.19%	-41.58%	-27.53%	-23.83%	-35.72%	-33.00%	Upgrade
Return on Capital Employed (ROCE)	-255.40%	-88.10%	-49.70%	-46.90%	-29.00%	433.30%	Upgrade
Earnings Yield	-289.86%	-15.26%	-43.86%	-22.21%	-35.95%	-	Upgrade
Buyback Yield / Dilution	-104.19%	-18.18%	-0.03%	-30.22%	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.